Abiomed Inc
ABMD
ABMD was delisted on the 21st of December, 2022.
517 hedge funds and large institutions have $10.5B invested in Abiomed Inc in 2022 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 189 increasing their positions, 176 reducing their positions, and 31 closing their positions.
243% more call options, than puts
Call options by funds: $48.7M | Put options by funds: $14.2M
81% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 31
4% more funds holding
Funds holding: 496 → 517 (+21)
7% more repeat investments, than reductions
Existing positions increased: 189 | Existing positions reduced: 176
0% more capital invested
Capital invested by funds: $10.5B → $10.5B (+$14.6M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$71.1M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$64.2M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$31.9M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$21.3M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$50.9M |
| 2 |
Renaissance Technologies
New York
|
-$48.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$29.9M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$29.3M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$22.9M |
ABMD Hedge Fund Activity: Q3 2022 in Review
517 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2022, worth a combined $10.5B — up 0.14% from $10.5B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ABMD positions and 31 closed out — a net gain of 25 holders — while 189 added to existing stakes and 176 trimmed.
The largest buyer was Vanguard Group, adding an estimated $77.7M. The largest seller was JP Morgan Chase, cutting an estimated $50.9M.
- 517 institutional investors held Abiomed Inc (ABMD) as of Q3 2022, up from 496 in Q2 2022.
- Funds reported $10.5B of Abiomed Inc stock for Q3 2022, up 0.14% quarter-over-quarter.
- 56 funds opened new Abiomed Inc positions in Q3 2022 and 31 closed out, a net change of +25 holders.
- The largest Abiomed Inc buyer in Q3 2022 was Vanguard Group, an estimated $77.7M added.
- The largest Abiomed Inc seller in Q3 2022 was JP Morgan Chase, an estimated $50.9M sold.
Based on aggregated 13F filings for Q3 2022.